Skip to content

Evaluation of the Role of Early Second Look TURBT in Management of High Risk Non Muscle Invasive Bladder Cancer

Evaluation of the Role of Early Second Look TURBT in Management of High Risk Non Muscle Invasive Bladder Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07642102
Enrollment
70
Registered
2026-06-11
Start date
2025-05-02
Completion date
2025-12-22
Last updated
2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Transurethral Resection of Bladder Tumor

Brief summary

The aim is to evaluate the intraoperative, postoperative and pathologic findings of early second look TURBT and the factors affecting these findings to assess the value of early second TURBT in the management of high risk NMIBC.

Interventions

PROCEDUREearly second look transurethral resection of bladder tumor

endoscopic early second look transurethral resection of bladder tumor after initial complete resection transurethral resection of non muscle invasive bladder tumor

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patients underwent initial complete resection TURBT with high risk non muscle invasive bladder cancer including: High grade T1 Any carcinoma in situ Any recurrent high grade Ta High grade Ta tumor size is more than 3 cm Any BCG failure in high grade patient Any variant histology Lymphovascular invasion High grade prostatic urethral involvement

Exclusion criteria

* \- Low risk non muscle invasive bladder cancer * intermediate risk non muscle invasive bladder cancer * muscle invasive bladder cancer * metastatic bladder cancer (positive lymph nodes or distant metastasis ) * absent muscle layer in the initial TURBT biopsies * incomplete resection initial TURBT

Design outcomes

Primary

MeasureTime frame
presence of pathologically positive tumor6 weeks

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 12, 2026